Marker Therapeutics MRKR Stock
Marker Therapeutics Price Chart
Marker Therapeutics MRKR Financial and Trading Overview
| Marker Therapeutics stock price | 1.3 USD |
| Previous Close | 1.37 USD |
| Open | 1.37 USD |
| Bid | 0.96 USD x 200 |
| Ask | 1.75 USD x 200 |
| Day's Range | 1.33 - 1.41 USD |
| 52 Week Range | 0.83 - 2.46 USD |
| Volume | 59.48K USD |
| Avg. Volume | 64.89K USD |
| Market Cap | 22.18M USD |
| Beta (5Y Monthly) | 1.514 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.87 USD |
MRKR Valuation Measures
| Enterprise Value | 10.84M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.5094342 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.252419 |
| Price/Book (mrq) | 1.8219178 |
| Enterprise Value/Revenue | 3.058 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Marker Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.514 |
| 52-Week Change | 53.93% |
| S&P500 52-Week Change | 20.20% |
| 52 Week High | 2.46 USD |
| 52 Week Low | 0.83 USD |
| 50-Day Moving Average | 1.31 USD |
| 200-Day Moving Average | 1.43 USD |
MRKR Share Statistics
| Avg. Volume (3 month) | 64.89K USD |
| Avg. Daily Volume (10-Days) | 102.9K USD |
| Shares Outstanding | 16.67M |
| Float | 13.74M |
| Short Ratio | 4.45 |
| % Held by Insiders | 5.49% |
| % Held by Institutions | 23.79% |
| Shares Short | 200.21K |
| Short % of Float | 1.47% |
| Short % of Shares Outstanding | 1.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -245.50% |
| Operating Margin (ttm) | -267.95% |
| Gross Margin | -148.27% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.46% |
| Return on Equity (ttm) | -76.86% |
Income Statement
| Revenue (ttm) | 3.55M USD |
| Revenue Per Share (ttm) | 0.19 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -5258892 USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -8707379 USD |
| Diluted EPS (ttm) | -0.37 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.33M USD |
| Total Cash Per Share (mrq) | 0.68 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.027 |
| Book Value Per Share (mrq) | 0.73 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9756497 USD |
| Levered Free Cash Flow (ttm) | -6227035 USD |
Profile of Marker Therapeutics
| Country | United States |
| State | TX |
| City | Houston |
| Address | 2450 Holcombe Blvd |
| ZIP | 77021 |
| Phone | 713 400 6400 |
| Website | https://markertherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Q&A For Marker Therapeutics Stock
What is a current MRKR stock price?
Marker Therapeutics MRKR stock price today per share is 1.3 USD.
How to purchase Marker Therapeutics stock?
You can buy MRKR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Marker Therapeutics?
The stock symbol or ticker of Marker Therapeutics is MRKR.
Which industry does the Marker Therapeutics company belong to?
The Marker Therapeutics industry is Biotechnology.
How many shares does Marker Therapeutics have in circulation?
The max supply of Marker Therapeutics shares is 16.67M.
What is Marker Therapeutics Price to Earnings Ratio (PE Ratio)?
Marker Therapeutics PE Ratio is now.
What was Marker Therapeutics earnings per share over the trailing 12 months (TTM)?
Marker Therapeutics EPS is -0.38 USD over the trailing 12 months.
Which sector does the Marker Therapeutics company belong to?
The Marker Therapeutics sector is Healthcare.
Marker Therapeutics MRKR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26099.77 USD — |
-1.03
|
5.81B USD — | 25995.53 USD — | 26260.68 USD — | — - | 5.81B USD — |
|
US Tech Health Care
IXHC
US
|
1346.8 USD — |
+0.49
|
— — | 1335.94 USD — | 1347.07 USD — | — - | — — |
- {{ link.label }} {{link}}
